2. Academic Validation
  3. Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with MYC/ IGH and BCL6/ IGH gene arrangements and potential molecular targeted therapies

Generation and characteristics of a novel "double-hit" high grade B-cell lymphoma cell line DH-My6 with MYC/ IGH and BCL6/ IGH gene arrangements and potential molecular targeted therapies

  • Oncotarget. 2018 Sep 11;9(71):33482-33499. doi: 10.18632/oncotarget.26060.
Hiroaki Kikuchi 1 2,  Tomonori Higuchi 1,  Yumiko Hashida 1,  Ayuko Taniguchi 3,  Mikio Kamioka 4,  Takahiro Taguchi 5,  Akihito Yokoyama 3,  Ichiro Murakami 6,  Mikiya Fujieda 2,  Masanori Daibata 1
Affiliations

Affiliations

  • 1 Department of Microbiology and Infection, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan.
  • 2 Department of Pediatrics, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan.
  • 3 Department of Hematology and Respiratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan.
  • 4 Department of Laboratory Medicine, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan.
  • 5 Department of Molecular and Cellular Biology, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan.
  • 6 Department of Pathology, Kochi Medical School, Kochi University, Nankoku, Kochi 783-8505, Japan.
PMID: 30323893 DOI: 10.18632/oncotarget.26060
Abstract

"Double-hit" lymphoma (DHL) is a high-grade B-cell lymphoma that harbors concurrent MYC and BCL2 or BCL6 rearrangements. Because cases of MYC/BCL6 DHL are uncommon, most reported conclusions have been based on cases of MYC/BCL2 DHL. Lack of experimental MYC/BCL6 DHL models continues to hinder the pathophysiologic and therapeutic investigations of this disorder. We herein describe a novel MYC/BCL6 DHL cell line, designated DH-My6, carrying both the MYC-IGH and BCL6-IGH fusion genes. Interruptions of MYC and BCL6 expressions using short interfering RNAs and chemical inhibitors led to significant attenuation of DH-My6 cell growth. Greater antitumor effects were found when the cells were treated with a combination of MYC and BCL6 inhibitors. Moreover, the PLK1 Inhibitor volasertib and the HDAC Inhibitor vorinostat synergized strongly when combined with the bromodomain inhibitor JQ1. DH-My6 is a new well-validated MYC/BCL6 DHL cell line that will provide a useful model for studies of the pathogenesis and therapeutics for the less common DHL tumor type. The rationale for approaches targeting both MYC and BCL6, and in combination with PLK1 or HDAC inhibitors for superior suppression of the aggressive MYC/BCL6 DHL warrants further in vivo testing in a preclinical model.

Keywords

BCL6; HDAC; MYC; PLK1; double hit lymphoma.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z